Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Ovarian Neoplasms 4Triple Negative Breast Neoplasms 2Solid Tumor 2Neoplasms 2Stomach Neoplasms 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Advanced Solid Tumor 1Advanced Cancer 1

Interventions

pembrolizumab 11Injections 10tislelizumab 7Nivolumab 4Irinotecan 4Cetuximab 4cediranib 3Paclitaxel 3PM 01183 3Leucovorin 3Gemcitabine 3Fluorouracil 3Cisplatin 3toripalimab 2spartalizumab 2serabelisib 2olaparib 2glumetinib 2camrelizumab 2apatinib 2adagrasib 2Therapeutics 2Pemetrexed 2Oxaliplatin 2Midazolam 2Drug Therapy 2Docetaxel 2Digoxin 2Cyclophosphamide 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Tumor × fluzoparib × Clear all
NCT04108676 2022-07-29

Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
16 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡